New AI and ML Capabilities Enhance DXRX Platform
Updated : 07:00
7 June 2022
Diaceutics PLC
("Diaceutics" or "the Company")
New AI and machine learning capabilities enhance DXRX platform
Deepening data insights and further embedding DXRX within customers' commercial processes
Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, intelligence, and analytics to the healthcare market has announced today significant enhancements to its proprietary DXRX platform, improving the user experience.
From within their DXRX dashboard, customers can now access three new AI-powered tools, helping to ensure their medicines get to patients quicker. They are Smart Trend Analysis, Next Best Step and Event Alerts.
- | Smart Trend Analysis: provides automated analysis of key trends and changes within customer data to uncover hidden insights including the production of bespoke, meaningful commentary for use in reports, with the customer able to customise the reports to focus on the datasets important to them |
- | Next Best Step: provides automated identification as to where in the ecosystem customers should target their diagnostics investments in order to get patients tested and treated faster |
- | Event Alerts: deliver just in time email notifications on significant changes within the data, such as if a new lab has started to offer diagnostic testing |
These services are highly sought-after by Diaceutics customers and previously relied on the expertise of the Diaceutics' data analysis team or availability of the customers' own data science resource. Now produced automatically, customer queries can be answered more comprehensively and faster than ever before.
This increased functionality represents a significant step in Diaceutics' strategy to embed its platform within its customers' own digital systems and day-to-day commercial processes.
Scott Gamester, Vice President of Data and Platform commented:
"This is an important new release for our customers, allowing a greater level of self service and flexibility when using the DXRX platform. Our smart trend analysis, next best step and event alert capabilities also recognise that our customers are busy executives and need these critical data insights as quickly as possible to support clinical and sales teams internally and physician prescribing externally.
All of this is made possible by our continued investment in platform innovation and supports Diaceutics' long term goal of seeing DXRX become an embedded part of the Pharma commercial model."
Enquiries:
Diaceutics PLC | |
Nick Roberts, Chief Financial Officer | Via Alma PR |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Stewart Wallace | |
Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Kieran Breheny | |
Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.